BioXcell熱銷產(chǎn)品--InVivoPlus anti-mouse PD-1 (CD279)
?
產(chǎn)品描述：
BioXcell InVivoPlus anti-mouse PD-1 RMP1-14單克隆抗體與小鼠PD-1（也稱為CD279）反應(yīng)。PD-1是一種50-55kDa的細(xì)胞表面受體，由Pdcd1基因編碼，屬于Ig超家族的CD28家族。PD-1在CD4和CD8胸腺細(xì)胞以及活化的T和B淋巴細(xì)胞和髓細(xì)胞上瞬時表達(dá)，在成功消除抗原后PD-1的表達(dá)下降。此外，在B細(xì)胞前階段，Pdcd1 mRNA在發(fā)育中的B淋巴細(xì)胞中表達(dá)。PD-1的結(jié)構(gòu)包括ITIM（基于免疫受體酪氨酸的抑制基序），這表明PD-1負(fù)調(diào)控TCR信號。PD-1通過結(jié)合B7家族的成員PD-L1和PD-L2發(fā)出信號。在配體結(jié)合后，PD-1信號傳導(dǎo)抑制T細(xì)胞活化，導(dǎo)致增殖減少，細(xì)胞因子產(chǎn)生和T細(xì)胞死亡。此外，PD-1敲除動物表現(xiàn)出擴(kuò)張型心肌病、脾腫大和外周耐受喪失，在小鼠的外周耐受性和預(yù)防自身免疫性疾病中發(fā)揮關(guān)鍵作用。誘導(dǎo)的PD-L1表達(dá)常見于許多腫瘤，包括鱗狀細(xì)胞癌、結(jié)腸癌和乳腺癌。PD-L1過度表達(dá)會導(dǎo)致腫瘤細(xì)胞對CD8T細(xì)胞介導(dǎo)的裂解的抗性增加。在黑素瘤的小鼠模型中，可以通過用阻斷PD-L1與其受體PD-1之間相互作用的抗體治療來暫時抑制腫瘤生長。由于這些原因，目前正在探索抗PD-1介導(dǎo)的免疫療法作為癌癥治療。與J43抗體一樣，RMP1-14抗體已顯示阻斷小鼠PD-L1-Ig和小鼠PD-L2-Ig與PD-1的結(jié)合。
產(chǎn)品詳情：
產(chǎn)品名稱 | InVivoPlus anti-mouse PD-1 (CD279) |
產(chǎn)品貨號 | BP0146 |
產(chǎn)品規(guī)格 | 5/25/50/100mg |
反應(yīng)種屬 | Mouse |
克隆號 | RMP1-14 |
同種型 | Rat IgG2a, κ |
免疫原 | Syrian Hamster BKH cells transfected with mouse PD-1 cDNA |
實(shí)驗應(yīng)用 | in vivo blocking of PD-1/PD-L signaling |
產(chǎn)品形式 | PBS, pH 7.0,Contains no stabilizers or preservatives |
純度 | >95%, Determined by SDS-PAGE |
聚合 | <5%, Determined by SEC |
無菌處理 | 0.2 μm filtration |
純化方式 | Protein G |
RRID | AB_10949053 |
分子量 | 150 kDa |
小鼠病原檢測 | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
保存條件 | 抗體原液保存在4°C，不能冷凍保存。 |
推薦同型對照 | InVivoPlus rat IgG2a isotype control, anti-trinitrophenol（貨號BP0089） |
推薦抗體稀釋液 | InVivoPure pH 7.0 Dilution Buffer（貨號IP0070） |
?
為什么選擇InVivoPlus抗體？
InVivoPlus級別的產(chǎn)品內(nèi)毒素含量更低，經(jīng)過多種實(shí)驗驗證，更適合用于體內(nèi)實(shí)驗研究
?
?
?
該產(chǎn)品自上市已被多篇SCI文獻(xiàn)引用，品質(zhì)有保證，以下是部分已發(fā)表的文獻(xiàn)引用：
應(yīng)用 | 文章 |
體內(nèi)PD-1/PD-L信號阻斷 (in vivo blocking of PD-1/PD-L signaling) | 1.?Triplett, T. A., et al. (2018). 'Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme' Nat Biotechnol 36(8): 758-764. 2.?Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100. 3.?Moynihan, K. D., et al. (2016). 'Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses' Nat Med. doi : 10.1038/nm.4200. 4.?Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811. 5.?Evans, E. E., et al. (2015). 'Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies' Cancer Immunol Res 3(6): 689-701. 6.?Zelenay, S., et al. (2015). 'Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity' Cell 162(6): 1257-1270. 7.?Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell Host Microbe 17(5): 628-641. |
?
更多產(chǎn)品詳情請咨詢 BioXcell 中國授權(quán)代理——欣博盛生物
全國服務(wù)熱線: 4006-800-892 ? ? ??郵箱: market@neobioscience.com?
深圳: 0755-26755892 ? ? ? ??北京: 010-88594029 ???????????
廣州：020-87615159????????? ?上海: 021-34613729
代理品牌網(wǎng)站: m.yuebanme.com?
自主品牌網(wǎng)站: www.neobioscience.net